In Business 32 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin Hydrochloride] [Alvespimycin]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
25 mg |
42 |
32 |
27 |
3200 |
| ||
|
100 mg |
87 |
66 |
55 |
6700 |
| ||
|
250 mg |
198 |
150 |
125 |
15200 |
| ||
|
500 mg |
262 |
199 |
166 |
20100 |
| ||
|
1 g |
475 |
361 |
300 |
36400 |
| ||
|
2 g |
825 |
627 |
521 |
63200 |
| ||
|
5 g |
1468 |
1115 |
928 |
112500 |
| ||
|
10 g |
2150 |
1633 |
1359 |
164800 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Prices and Purity — LC Labs vs. Other Suppliers |
|---|
M.W. 653.21
C32H48N4O8•HCl
[150270-08-9]
Warning: Toxic.
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO; soluble up to about 2 mg/mL in water. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
Synthetic derivative of geldanamycin, Cat. No. G-4500, and water-soluble analog of 17-AAG, Cat. No. A-6880, demonstrating stability and low in vivo toxicity similar to 17-AAG, but undergoes limited metabolism compared to 17-AAG. Egorin, M.J., et al. "Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats." Cancer Chemother. Pharmacol. 49: 7-19 (2002).
Binds specifically to heat shock protein Hsp90 in a manner similar to geldanamycin. Tian, Z.Q., et al. "Synthesis and biological activities of novel 17-aminogeldanamycin derivatives." Bioorg. Med. Chem. 12: 5317-5329 (2004).
Inhibits angiogenesis. Kaur, G, et al. "Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator." Clin. Cancer Res. 10: 4813-4821 (2004).
Enhances the radiation-induced cell cycle arrest of human solid tumor cell lines both in vitro and in vivo. Bull, E.E., et al. "Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin." Clin. Cancer Res. 10: 8077-8084 (2004).
Exhibits potent anti-tumor activity against MDA-MB-231 breast carcinoma cells and HL60-TB leukemia cells both of which are relatively insensitive to 17-AAG. Hollingshead, M., et al. "In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative." Cancer Chemother. Pharmacol. 56: 115-125 (2005).
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.
